PharmaShots | Incisive News in 3 Shots

Subscribe Now

CF

Boehringer Ingelheim Exercised its Option to License Oxford Biomedica's Lentiviral Vector Technology to Commercialize BI 3720931 for CF

Boehringer Ingelheim Exercised its Option to License Oxford Biomedica's Lentiviral Vector Technology to Commercialize BI 3720931 f...

October 20, 2021

Vertex's Kalydeco (ivacaftor) Receives Health Canada's Approval for Cystic Fibrosis (CF) with CFTR Gene Mutation in Children Aged 12 to

Vertex's Kalydeco (ivacaftor) Receives Health Canada's Approval for Cystic Fibrosis (CF) with CFTR Gene Mutation in Children Aged...

January 29, 2019

Vertex's Orkambi (lumacaftor/ivacaftor) Receives Health Canada Approval for Cystic Fibrosis (CF) Aged 2 to 5 yrs.

Vertex's Orkambi (lumacaftor/ivacaftor) Receives Health Canada Approval for Cystic Fibrosis (CF) Aged 2 to 5 yrs.

December 14, 2018

Vertex Receives EU's MAA for Symkevi (tezacaftor/ivacaftor) + Kalydeco (Ivacaftor) to Treat Patients with CF aged ≥12yrs. with Mutations in CFTR gene

Vertex Receives EU's MAA for Symkevi (tezacaftor/ivacaftor) + Kalydeco (Ivacaftor) to Treat Patients with CF aged ≥12yrs. with Mut...

November 2, 2018

Contact Us

First Floor, B-66, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
connect@pharmashots.com
Newsletter

Our Information

Follow Us